Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects With Advanced Malignancies

NCT01284192 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01284192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01284192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP3026 in Subjects With Advanced Malignancies
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
March 31, 2016
Enrollment
46 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies, b-cell lymphoma, positive for anaplastic lymphoma kinase, positive for proto-oncogene tyrosine-protein kinase ros, solid tumor